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Responsible use of antibiotics and concerns surrounding antimicrobial resistance (AMR) are 
pervading all areas of both veterinary and human medicine. It is the prescribing clinician's 
responsibility to ensure that the use of antimicrobials is justified in all situations. 
Increasingly, the assurances justifying the prescription and use of antibiotics are under 
scrutiny and may in the future be subject to challenge on a number of fronts. The routine use 
of antibiotics at drying off in dairy cows is one such area of reappraisal and challenge. 
In order to validate and uphold the principles of responsible use of antimicrobials, analysis of 
past prescribing practices and outcomes must be combined with robust clinical research 
evidence. Even a cursory analysis of on-farm and within-practice data has the potential to 
influence future prescribing; challenging and reappraising the necessity for antibiotic 
prescribing in certain clinical situations has been known to lead to a marked reduction in 
antibiotic use. 
When critically appraising the current approach to drying off dairy cows, it is worth looking 
not only at current and future drivers for change but also at how we got to where we are 
today. Many factors have influenced the approach to managing dairy cows at the end of 
lactation: the social environment (attitudes to antibiotic use), pharmacological environment 
(products available) and physical environment that cows occupy have all seen significant 
change. 
Antibiotic dry cow therapy (aDCT) was introduced in the 1950s as part of a structured 
mastitis control plan (Five-Point Mastitis Control Plan) developed at the National Institute for 
Research in Dairying at the University of Reading. Slow release antibiotic preparations 
infused into each quarter of a cow at drying off not only improved the chance of elimination 
of existing intramammary infections (IMI) but also afforded the cow some protection from 
new IMI during the dry period. Hence, this practice became an important component in the 
management of dry cows. Over time, the prevalence of persistent contagious pathogens has 
declined, and the need for blanket antibiotic therapy in every cow at drying off to improve 
cure rates over the dry period has diminished and can therefore no longer be justified on most 
UK dairy farms. 
Since the dry period is a particularly high risk for the establishment of new IMI in the dairy 
cow, various attempts have been made to impart protection, including the application of 
Stockholm Tar and external teat sealants (‘plastic skin’) to teats; these were not particularly 
effective, nor were they easy to apply. The development of bismuth subnitrate-based internal 
teat seals (iTS) in Ireland and their subsequent introduction to the UK in 2002 heralded a 
significant improvement in protection from new IMI during the dry period. Initially used as 
an alternative to aDCT, iTS soon became used in combination with aDCT, a practice that is 
common throughout the dairy industry in the UK today. 
It can be argued that all cows, whether uninfected or infected (and then cured), are 
susceptible to new infection in the dry period and therefore justify the protection afforded by 
iTS administered at drying off. However, the same cannot be said about administration of 
aDCT to all cows at drying off. There needs to be a paradigm shift from the decades of 
blanket aDCT irrespective of udder infection status to rational prescription and administration 
of aDCT based on the risk of an intramammary infection being present. In other situations 
when faced with infectious diseases, such as calf pneumonia, decisions are around identifying 
which calves to treat with antibiotic, not which calves not to treat. Rather than thinking about 
the problem of deciding which cows should not receive aDCT, we believe decisions should 
instead be based around which cows justify aDCT, so that antimicrobial products can be 
targeted towards cows likely to have major pathogen IMI at drying off. The approach to dairy 
cows at drying off can therefore be summed up as: ‘Underwrite the whole herd with iTS and 
target aDCT to those cows that justify it’, while maintaining the responsible approach of 
using ‘as little antibiotic as possible but as much as necessary’. 
Identifying cows that justify antibiotic therapy at drying off 
Methods to assess the risk of the presence of an IMI include direct methods, such as detection 
of bacteria by culture or PCR, or indirect methods, such as California Milk Test (CMT) or 
individual cow somatic cell count (ICSCC). Assessment of the relative risk of a cow having 
an IMI at drying off may also be influenced by clinical mastitis history from farm records or 
observation of teat lesions at the time of drying off. All methods of diagnosis will have 
inherent false-negative and false-positive rates that depend on the sensitivity (Sn) and 
specificity (Sp) of each test and the predictive positive and predictive negative values, 
respectively, within the population in which they are being used. 
Cure rates of IMI will vary for a number of reasons (including the causal pathogen); however, 
during the dry period, cure rates are significantly higher than during lactation so, arguably, 
tests used to identify IMI at drying off should be optimised for the detection of infected cows 
(Sn) to avoid missing that opportunity for cure. When availability, practicality, Sn, Sp and 
cost of data are taken into account, the use of regular routine ICSCC (most commonly 
performed monthly) in combination with clinical mastitis case records is often the most 
appropriate approach. ICSCC has the advantage that changing the threshold used to 
determine the risk of infection can alter Sn and Sp, albeit with a trade-off that lower 
thresholds will improve Sn to the detriment of Sp, while higher thresholds will improve Sp to 
the detriment of Sn. The internationally accepted individual cow threshold of 200,000 
cells/ml is optimised for balanced Sn and Sp. However, primiparous cows (heifers) generally 
have lower ICSCC, and therefore thresholds should be set appropriately lower than for 
multiparous cows. 
Although decisions to use aDCT are made at an individual cow level, the herd characteristics 
will influence those decisions. The prevalence of IMI in a herd – broadly indicated by the 
bulk milk somatic cell count (BMSCC) – will influence the positive predictive value for any 
given threshold (the probability that cows above the threshold have an infection). Therefore, 
herds with low BMSCC should use a higher ICSCC threshold to justify aDCT, while herds 
with a higher BMSCC should use a lower ICSCC threshold to justify aDCT (Table 1). In our 
view, the criteria to justify aDCT should be bespoke for each dairy farm, and should be 
expected to change over time, based on farmer and veterinary knowledge of predominant 
pathogens, BMSCC, mastitis management and risk to the cow. Targeting aDCT towards 
cows likely to have a major pathogen IMI at drying off should be influenced by the available 
data indicating likely infection status at drying off. Cows with an IMI in early lactation 
(either a clinical case or elevated ICSCC above threshold), where data towards the end of 
lactation indicate that an IMI with a major pathogen is unlikely, do not justify aDCT at 
drying off; for example, a cow with a self-limiting E coli clinical case within one month of 
calving with no further clinical cases and an ICSCC that remains below threshold for the rest 
of the lactation would not need aDCT. 
 
Consequently, criteria such as no clinical mastitis or ICSCC above the threshold within, for 
example, the past three months of lactation rather than within the whole lactation should be 
set to evaluate the likelihood of an IMI with a major pathogen at drying off. In some herds it 
may be appropriate to use quarter level tests at drying off (such as the CMT) to improve Sn. 
Although a ‘one size fits all’ ICSCC threshold (eg, 200,000 cells/ml for all herds) might seem 
a simple solution, we feel that this approach will put many herds, particularly those with a 
low BMSCC, at risk of treating too many uninfected cows with aDCT, while herds struggling 
with a higher BMSCC may find they miss that golden opportunity to cure many unidentified 
infected cows during the dry period, with a resultant increase in BMSCC over time. Indeed, 
since the BMSCC and pathogen profile of a herd is likely to change over time, there is a need 
to continually refresh and re-evaluate the thresholds needed to apply targeted aDCT. 
The authors of this article have been working with farmers to implement a selective approach 
to the use of aDCT for many years. However, we feel there is now a golden opportunity for 
all practitioners to engage in advising dairy farmers on selective or targeted aDCT. Increased, 
continuous veterinary involvement in these on-farm decisions can make a meaningful 
contribution to responsible prescribing of antibiotics to dairy cows without compromising the 
many years of hard work that have gone into to achieving the current laudable UK BMSCC 
national average. 
TABLE 1: 
An example of how a sliding scale of thresholds for making decisions to use targeted 
antimicrobial dry cow therapy (aDCT) might be applied 
 ICSCC threshold x 1000 cells/ml 
BMSCC x 1000 
cells/ml Multiparous cows Primiparous cows 
<100 250 200 
100 - 150 200 150 
150 - 200 150 100 
200 - 250 100 50 
>250 
A low threshold could be used (eg, 50) otherwise selective/targeted aDCT 
may not be appropriate until the BMSCC is reduced 
BMSCC The prevalence of intramammary infections in a herd, broadly indicated by the bulk 
milk somatic cell count; ICSCC Individual cow somatic cell count 
 
